Citius OncologyCTOR
13F holders, Q4 2025 (December 31)18holders +2
6new positions
4sold out
$1.00avg. 13F price*
At the end of Q4 2025, 18 institutions reported holding Citius Oncology Inc. (CTOR) in their 13F filings, up 2 from Q3 2025. 6 opened new positions and 4 sold out. The largest holders were Armistice Capital, LLC ($5.6M), Vanguard Group Inc. ($597K) and Geode Capital Management, LLC ($220K).
- Company
- Citius Oncology Inc.
- CUSIP
- 17331Y109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $165K |
| Exits | 4 | $173K |
All 13F filers, Q3 2025 → Q4 2025: 734,546 shares bought and 2,230,505 shares sold, net −1,495,959 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Armistice Capital, LLC | 0.14% | Reduce -27.3% | 5,584,080 | $5.6M |
| Vanguard Group Inc. | 0.00% | Add +231.4% | 596,997 | $597K |
| Geode Capital Management, LLC | 0.00% | Add +31.6% | 220,047 | $220K |
| OMERS ADMINISTRATION Corp | 0.00% | New | 104,500 | $105K |
| IFP Advisors, Inc | 0.00% | Add +163.2% | 87,424 | $87K |
| XTX Topco Ltd | 0.00% | Reduce -41.7% | 73,992 | $74K |
| Northern Trust Corp. | 0.00% | Add +110.2% | 45,746 | $46K |
| State Street Corp. | 0.00% | No change | 42,900 | $43K |
| Two Sigma Investments, LP | 0.00% | New | 23,515 | $24K |
| BlackRock, Inc. | 0.00% | New | 22,344 | $22K |
| UBS Group AG | 0.00% | Add +38925.4% | 21,464 | $21K |
| Two Sigma Securities, LLC | 0.00% | New | 13,360 | $13K |
| Arkadios Wealth Advisors | 0.00% | No change | 11,666 | $12K |
| Osaic Holdings, Inc. | 0.00% | Reduce -2.7% | 11,425 | $11K |
| Versant Capital Management, Inc | 0.00% | New | 1,500 | $2K |
| Bank of America Corp. | 0.00% | Reduce -18.9% | 214 | $214 |
| Farther Finance Advisors, LLC | 0.00% | No change | 3 | $3 |
| Royal Bank of Canada | 0.00% | New | 23 | $0 |
"% of holder's portfolio" is CTOR's weight in each manager's 13F, not the share of Citius Oncology Inc. the manager owns.